INTRODUCTION
Inositol hexaphosphate (IP 6 , InsP 6 ) is ubiquitous in plants, such as cereal and legumes, and is found in most mammalian cells at concentrations of 10 µM to 1 mM (1,2). Recognized as a strong antioxidant (3), IP 6 has also been shown to play a critical role in neurotransmission (4), regulation of vesicle trafficking and recycling (5) , and endo-and exocytosis (6) . These activities are mediated by protein kinase C (PKC) (6) , modulation of calcium influx coupled to the inhibition of phosphatases (7), and efficient messenger RNA export (8, 9) . A novel anti-cancer function of IP 6 has been demonstrated both in vivo and in vitro (10) (11) (12) , acting primarily via regulation of cell growth and cell differentiation (10) (11) (12) (13) (14) . The potential of IP 6 to reduce tumor incidence and tumor load has been shown in rodent mammary tumors (15) (16) (17) (18) , colon tumors (19) (20) (21) (22) (23) , and in other experimental models, including transplanted and metastatic fibrosarcoma (24) , rhabdomyosarcoma (25) , and hepatoma (26, 27) . IP 6 is abundantly present in mammalian cells, is a component of a regular diet, is safe and efficiently absorbed from the gastrointestinal tract (1, 28, 29) , and, therefore, represents an excellent preventive and therapeutic candidate for various tumors. However, all studies addressing the anti-cancer action of IP 6 have been performed with malignant epithelial cells, with no published reports of the effect of IP 6 on vascular endothelial cells and angiogenesis.
Angiogenesis is the process of blood vessel formation that occurs under physiological and pathological conditions; in particular, angiogenesis is associated with progressive growth and metastasis of solid tumors, which depend on recruitment of new blood vessels (30) (31) (32) (33) . The induction of tumor vascularization is mediated by the release of angiogenic factors. Among these factors, vascular endothelial growth factor (VEGF) is thought to be the most specific (34) . VEGF is secreted by tumor cells, and promotes the proliferation of endothelial cells and remodeling of neo-vessels. Since endothelial cells can communicate directly with tumor cells by producing growth promoting factors, the inter-relationship between endothelial and tumor cells and the imbalance between angiogenic factors and angiogenic inhibitors can promote tumor vascularization. Identification of novel angiogenic inhibitors that target both the proliferating endothelial and tumor cell compartments may, therefore, lead to therapeutic regulation of tumor growth.
Several angiogenic inhibitors that regulate vascular endothelial cell proliferation by targeting angiogenic factors or their receptors have been developed (34, 35) . Thalidomide (36) (37) (38) and TNP-470 (39, 40) , inhibitors of endothelial cell growth, are in clinical trial. VEGF, its receptor VEGFR-2, and novel small-molecule inhibitors of VEGFR-2, such as SU5416, are currently the targets of intense efforts to inhibit dysregulated blood vessel formation in cancer (35) . Angiostatin, an internal fragment of plasminogen containing 4 kringle domains (41) and endostatin, a C-terminal fragment of collagen XVIII from hemangioendothelioma (42) , are endogenous inhibitors of angiogenesis. Additionally, a number of compounds with anti-angiogenic activity have been derived from plants, such as genistein, isoliquitrin, and ginsenoside. Recently, the anti-angiogenic potential of sylmarin, a polyphenolic flavonoid antioxidant isolated from milk thistle, Silybum marianum (L.) Gaertn (43) , torilin, isolated from Torilis japonica (44) , and catechins from green tea extracts (45) have been reported.
In our study, we evaluated the anti-angiogenic activity of IP 6 . We hypothesize that IP 6 inhibits tumor angiogenesis by affecting both vascular endothelial cells and tumor cells. We report that IP 6 reduced angiogenesis in vivo and inhibited proliferation and differentiation of endothelial cells in vitro. The development of more successful anti-angiogenic therapy requires combined treatment directed to different cellular compartments. Therefore, we further tested IP 6 in combination with vasostatin, a small calreticulin fragment, with anti-angiogenic properties directed primarily to endothelial cells (46) (47) (48) , and found that the combination of IP 6 and vasostatin was synergistically superior in growth inhibition than each compound alone. In addition, we report an inhibitory action of IP 6 on the secretion of the primary angiogenic cytokine, VEGF, by a human liver cancer cell line.
MATERIALS AND METHODS Cell Lines and Cell Culture
Human umbilical vein endothelial cells (HUVECs), obtained from Clonetics (San Diego, CA), were maintained and propagated in Medium 199(E) containing 10% fetal bovine serum (FBS), 2 mM Lglutamine, 50 µg/mL bovine pituitary extract (Gibco BRL Life Techonologies Inc., Gaithersburg, MD), 10 ng/mL of EGF (Gibco BRL), and 50 µg/mL of gentamycin (Gibco BRL). HUVECs were used between passages 4 and 10. HUVEC retrovirus telomerized (HRVT) cells were created in our laboratory from the human dermal microvascular endothelial cells as described previously (49) . HRVT cells were used between passages 20 and 30, and were maintained and grown in Medium 199(E) (Gibco BRL). These cells are equivalent to the early passages of HUVECs. Bovine aortic endothelial cells (BAECs), from Coriell (Camden, NJ) and HepG2, human hepatoblastoma cell line, obtained from the American Type Culture Collection (Rockville, MD) were grown in DMEM medium (Gibco BRL) supplemented with 10% FBS, 2 mM L-glutamine, 50 U/mL of penicillin, and 50 µg/mL of streptomycin. Cell cultures were maintained in a humidified 37 o C incubator with 5% CO 2 . IP 6 IP 6 , as a dodecasodium salt from rice (Sigma Chemical Co., St. Louis, MO), was prepared as a 100 mM stock solution in distilled water at pH 7.4. This stock solution was further diluted to the desired concentration with culture medium. Fresh IP 6 stock solution was prepared before use. Vasostatin Vasostatin was purified and expressed as described before (50) . In brief, a bacterial maltose-binding protein (MBP) fusion system was used to express recombinant protein; bacterial strain was E. Coli BL21 (λDE3), and plasmid pMAL-c2. Vasostatin is a N-domain of human calreticulin (residues 1-180). A P-domain of calreticulin (residues 181-290) (PDN) and MBP2 (MBP) (New England Biolabs, Hitchin, Hertfordshire, UK) were tested as control proteins. All proteins were dialysed into endotoxinfree water containing 10 mM NaCl and freeze-dried.
Growth Inhibition Assay
To evaluate the effect of IP 6 on the proliferation of BAECs, a colorimetric MTT assay was used as previously described (13, 25, 26) . This assay measures the reduction of a tetrazolium salt, MTT ([4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide) (Sigma) by living cells to a blue-colored formazan product, evaluating mitochondrial as well as the antiproliferative activity. Cells were plated in 96-well microtiter plates (Sarstedt, Inc., Newton, NC) at a density of 2x10 3 cells/well/100 µL and treated either with various concentrations of IP 6 , ranging from 0.1 mM to 3.0 mM, or vasostatin, ranging from 0.1 µg/mL to 10 µg/mL, or their combinations. After 1, 3, and 5 days of treatment, 50 µL of MTT (1.0 mg/mL) was added, and the incubation continued for 4 h at 37 o C. The precipitated formazan was solubilized with 150 µL of DMSO (Sigma) and the absorbance was determined at 540 nm. The MTT assay was performed with BAECs grown in the presence or absence of bFGF (10 µg/mL). Mean and standard deviations were from triplicate data points. Independent experiments were repeated three times.
Plating Efficiency Assay
BAECs were seeded on 10-cm tissue culture dishes (Sarstedt) at a density of 5x10 3 cells/dish and incubated at 5% CO 2 for 10 days. The growth medium contained various concentrations of either IP 6 (ranging from 0.1 mM to 3.0 mM) or vasostatin (ranging from 0.1 µg/mL to 10 µg/mL) or their combinations; for control, BAECs of the same density were plated in dishes containing growth medium only. BAECs were seeded in triplicates, and this experiment was repeated thrice.
Capillary Tube Formation on Matrigel (In vitro Angiogenesis)
In experiments assessing the inhibitory effect of IP 6 on capillary tube formation, HUVECs and HRVT cells were cultured in 24-well plates on a 0.2 mL layer of previously polymerized Matrigel (Becton Dickinson, Bedford, MA) with or without IP 6 , as described previously (51) . HUVECs were plated in triplicate at a density of 10 5 cells per well, while HRVT cells were seeded between 7-8 x 10 4 cells per well. In this assay, cells attach within 30 min, become growth arrested, migrate, secrete proteases to invade into the gel, and form inter-connecting networks within 6 h. Complete differentiation is usually achieved after 18-24 h. The networks are stable for several days, after which regression and aggregation occurs. Changes of cell morphology influenced by the presence of IP 6 , were captured after 4 and 22 h through a phase contrast microscope (x40) (Zeiss Axiovert 10, Germany) and photographed with a CCD video camera. To investigate the effect of IP 6 on pre-formed tubes, HUVECs and HRVT cells were seeded onto Matrigel for 6 h to form rudimentary tubes, then the medium was replaced and IP 6 was added. Tube morphology was observed over time, and representative pictures were taken 24 h after the initiation of IP 6 treatment. Independent experiments were repeated twice.
In vivo Mouse Matrigel Plug Assay
The mouse Matrigel plug assay was performed as previously described by Passaniti et al. (52) . IP 6 (2.0 mM) and bFGF (400 ng/mL) in PBS were mixed with Matrigel (Becton Dickinson, Bedford, MA) in proportions not exceeding 1% of the total volume of Matrigel. A mixture of 0.5 mL Matrigel with IP 6 or vehicle and/or bFGF were injected s.c. into C57BL/6J mice. The study was approved by the University of Maryland School of Medicine Animal Care and Use Committee, and performed in accordance with current regulations and standards of the NIH and our institutional guidelines for animal care. Since IP 6 is a water soluble compound that might diffuse easily from the plugs, to ensure adequate exposure to IP 6 , the experimental groups were also given IP 6 in drinking water (2% w/v, 15 mM), as described previously (15) (16) (17) (19) (20) (21) . After 5-7 days, mice were sacrificed, and the excised Matrigel plugs were fixed and stained using the Masson-Trichrome method. The experiment was repeated twice using 5 mice per data point. For quantitative analysis of angiogenesis in Matrigel plugs, a computerized digital system and NIH Image-1 software was used on images captured as TIF files. The relative angiogenic response was evaluated from the cellular density of each slide after background substraction.
VEGF Secretion by Cancer Cells
The production of VEGF angiogenic factor in response to IP 6 treatment was measured in HepG2 cells. To study the effect of IP 6 on production and expression of VEGF mRNA, we used Reverse Transcription-Polymerase Chain Reaction (RT-PCR) (53) . Total RNA was isolated from HepG2 cells treated with IP 6 after 8 and 24 h using RNAzol (Tel-Test Inc., Friendswoods, TX) extraction procedure according to the manufacturer´s protocol. For a positive control, total RNA was extracted from the prostate carcinoma cell line, LNCaP. RT-PCR was used to amplify cDNAs. After the RT reaction with Superscript II reverse transcriptase (Gibco BRL, Grand Island, NY), PCR was used to identify the presence of VEGF isoforms in the RNA samples. Primers used for the amplification assay were slight modification of those published previously. Because these primers initiate within the first exon and terminate within the eighth exon of VEGF-A, they enable amplification of all the known VEGF splice variants. The oligonucleoide sequences of the primers used were: 5´human start of exon 1 5´TGC ACC CAT GGC AGA AGG AGG 3 3´human end of exon 8 5´TCA CCG CCT CGG CTT GTC ACA 3 PCR was carried out with Taq DNA polymerase (Boehringer Mannheim Biochemicals, Indianopolis, IN) with a DNA Thermal Cycler (Perkin Elmer Cetus, Norwalk, CT) as follows: 94 o C for 7 min, then 35 cycles of denaturation at 94 o C for 1 min, annealing and extension at 72 o C for 1 min each. The PCR products were analyzed by electrophoresis on a 2% agarose gel that was subsequently stained with ethidium bromide for visualization of DNA bands. A 100 base pair (bp) ladder DNA molecular weight marker (Boehringer Mannheim Biochemicals) was used to provide a size reference for the test reaction. The samples were run in duplicates for each time point. The experiment was performed independently twice.
To investigate the effect of IP 6 on the secretion of VEGF protein from cancer cells, HepG2 cells were grown in T25 flasks in complete medium until confluent. The medium was removed, cells were washed thrice with PBS, and then treated in serum-free medium with increasing concentrations of IP 6 . Serial 1-ml aliquots were removed from the culture media for VEGF analysis after 1, 3, 6 and 24 h. In a second set of experiment, cells were pre-treated with increasing concentrations of IP 6 for 24 h, media were replaced with serum-free media, and then 1-ml aliquots were collected. Samples were analyzed for VEGF protein content by an ELISA kit following manufacturer's instructions (R&D Systems, Minneapolis, MN). To express the protein levels of VEGF in tissue culture media, we determined the protein levels by the Bio-Rad protein determination assay kit, based on Bradford method, and normalized the results relative to the protein levels. The experiment was repeated. Each sample was measured in triplicate.
Statistical analysis
The mean and standard deviations were calculated. The results were evaluated either by Student's t-test or ANOVA for multiple group comparisons using Prism (GraphPad Software, San Diego, CA). Synergism was detected by the median effect equation as described by Chou and Talalay (54) . The extent of interaction between the compounds was determined by using the combination index (CI), where CI < 1.0 signified synergism, CI = 1.0 additive effect, and CI > 1.0 antagonism.
RESULTS

Inhibition of endothelial cell proliferation by IP 6 in vitro
Since angiogenesis critically depends on the ability of endothelial cells to proliferate, we investigated the anti-angiogenic activity of IP 6 by first studying its effect on the proliferation of endothelial cells by monitoring the growth and plating efficiency of endothelial cells treated with IP 6 . Different doses of IP 6 ranging 0 -3.0 mM were applied to BAECs and the effect on their growth was determined by MTT assay. IP 6 inhibited the growth of BAECs in a dose-dependent manner, with an IC 50 of 0.74 mM on day 3 ( Figure 1A ). While lower concentrations of IP 6 (0.1 and 0.3 mM) had no effect on the growth compared with the control, the growth was significantly inhibited by 0.6 mM (p < 0.01; 84 % on day 3, 62 % on day 5), and completely suppressed at concentrations ≥ 1.0 mM ( Figure  1A ). Similar results were obtained when the growth of BAECs was stimulated by bFGF (10 µg/mL) (data not shown). However, in the presence of bFGF, cells grow faster, reaching a plateau earlier, not allowing good evaluation of a growth rate. It is important to note that these IP 6 concentrations are typically found in mammalian cells (1, 2) , used for in vitro experiments, and that 2.0 mM inositol hexasulphate, a structural analogue of IP 6 , used as additional control, had no effect on growth of either endothelial cells (data not shown) or epithelial cells (14) , indicating the specific effect of IP 6 .
Since vasostatin directly targets endothelial cells, we further tested IP 6 in combination with vasostatin. As expected, a strong, concentration-dependent growth inhibition of BAECs by vasostatin was observed: 65% inhibition with concentration of 3 µg/mL, and with IC 50 of 2.33 µg/mL on day 3 ( Figure 1B ). The specificity of this response was confirmed by the inability of control proteins, MBP and PDN (not shown), to suppress the growth of BAECs at concentrations ranging 0.1 -10 µg/mL ( Figure 1D ). However, when BAECs cells were treated with the combination of IP 6 and vasostatin a synergistic response was obtained with CI of 0.22 at day 3, and 0.33 at day 5 (note that CI < 1.0 signifies synergism [54] ) ( Figure 1C ). All combinations of all concentrations of IP 6 and vasostatin were performed, also in the presence and absence of bFGF. Although observed with 0.3 mM IP 6 , the most dramatic combination effect was obtained with 0.6 mM IP 6 .
Additionally, in a plating efficiency assay, IP 6 or vasostatin inhibited colony formation of BAECs (Figure 2A, B and C) . Concentration of 1 µg/mL of vasostatin exhibited a stronger ability to prevent BAECs colony formation than 0.6 mM IP 6 ( Figure 3C ). Reduced plating efficiency can result from both decreased proliferation and reduced attachment of cells in the presence of IP 6 and vasostatin. Actually, the ability of IP 6 to reduce adhesion of human breast cancer cells was recently reported from our laboratory (55) . Furthermore, it appears that vasostatin at this concentration exhibited a stronger ability to prevent BAECs colony formation than to inhibit BAECs growth, as judged from the MTT assay ( Figure 1B) , suggesting that vasostatin inhibits attachment of cells. However, similar to MTT, a synergistic response of IP 6 in combination with vasostatin was observed in this assay, achieving almost a complete inhibition of BAECs colony formation ( Figure 2D ). In contrast, control proteins MBP and PDN, did not affect the ability of BAEC to form colonies when tested alone or in combination with IP 6 (data not shown).
Inhibition of differentiation of endothelial cells by IP 6 in vitro
To determine whether IP 6 had an inhibitory effect on differentiation and tube formation of vascular endothelial cells, we conducted the experiments in an in vitro angiogenesis model using HUVECs and HRVT cells seeded on Matrigel (a reconstituted extracellular matrix preparation of EHS mouse sarcoma). These cells undergo rapid in vitro differentiation into capillary like structures, a complex process that requires cell-matrix interaction, intercellular communication, and cell motility. IP 6 exhibited a striking inhibitory effect on capillary tube formation in this model. The treatment was initiated simultaneously with the seeding of cells on Matrigel. As shown in Figure 3A , both HUVECs and HRVT cells formed inter-connected networks and hollow tubes on Matrigel; in control cells, these structures became stronger, more robust and longer with time. In contrast, IP 6 inhibited tube formation of HUVECs in a time-and dose-dependent fashion (data after 4 h not shown). After 22 h of exposure to 0.3 mM IP 6 there was near total inhibition of network formation by both cell lines, reflecting the inhibition of attachment, migration, and invasion of cells by IP 6 ( Figure 3A) . Interestingly, HRVT cells were more sensitive, showing inhibition of tube formation at 0.05 mM IP 6 . Representative fields from three independent experiments are shown ( Figure 3A) . To evaluate whether IP 6 could also disrupt preexisting tubes, HUVECs and HRVT cells were treated with IP 6 6 h after seeding on Matrigel. Exposure of these pre-formed tubes to 1.0 mM IP 6 for 24 h resulted in the retraction of cells and disintegration of tubes ( Figure 3B ). It is important to note that these cells were alive. In doses used in majority of in vitro studies, IP 6 appears to be a cytostatic, not a cytotoxic agent. No cytotoxicity of endothelial cells was observed up to 3.0 mM IP 6 , a dose higher than those used in the differentiation assay, tube formation, and tube regression assay, as reported previously for colon and breast cancer cells (56) .
Inhibition of angiogenesis by IP 6 in an in vivo mouse model
To further assess the anti-angiogenic potential of IP 6 , we used an in vivo assay, in which Matrigel plugs were impregnated with bFGF, as an inducer of neovascularization (57) . In addition to 2 mM IP 6 incorporated into plugs, mice were given 2% IP 6 in drinking water (w/v, 15 mM), because IP 6 , as a water-soluble compound, could diffuse easily from the plugs. IP 6 in the plugs was able to inhibit neovascularization induced by bFGF. However, this effect was much more pronounced when in addition to plugs, IP 6 was given in a drinking water. In these assays the tissue response to bFGF includes endothelial cell proliferation and migration and increased density within the gel plug ( Figure  4A ). Red blood cells were abundant within the lumen of numerous vessels (arrows, Figure 4A) . However, IP 6 in combination with bFGF almost completely inhibited vessel induction, indicating that IP 6 potently suppressed the bFGF-stimulated angiogenesis in mice ( Figure 4B ). As a result of IP 6 -suppressed cellular infiltration and functional neovessel formation within the Matrigel plugs, the relative cellular density of the plugs was 75% smaller when compared to control (p < 0.001), equal to the response observed in the absence of bFGF ( Figure 4C ).
Inhibition of VEGF expression and secretion by IP 6 in HepG2 cells
Having established the anti-angiogenic activity of IP 6 on endothelial cells, we conducted studies to explore the effects of IP 6 on the expression and secretion of a primary angiogenic cytokine VEGF by HepG2 cells, a human liver cancer cell line, because VEGF is expressed in these cells (57) , and because IP 6 inhibited tumor growth leading to regression of the HepG2 tumors in a transplanted nude mouse model (26, 27) . We previously showed that IP 6 treatment of HepG2 cells caused a dosedependent growth inhibition (26) . When inoculated into athymic nude mice, IP 6 significantly reduced the growth of these human hepatoma tumors, leading to tumor regression (27) . To test whether IP 6 has the ability to reduce the expression and secretion of VEGF by HepG2 cells in vitro, first we evaluated its effect on VEGF mRNA expression, using RT-PCR. In a second set of experiments, we evaluated the ability of IP 6 to reduce the secretion of VEGF protein from the cancerous HepG2 cells.
HepG2 cells showed strong expression of three mRNA isoforms: 122, 165 and 189 ( Figure 5A ). IP 6 treatment of HepG2 cells for 8 h induced a marked down-regulation of mRNA expression of all VEGF isoforms in a dose-dependent fashion (p < 0.001) ( Figure 5A ). To determine whether IP 6 would down-regulate the expression of VEGF protein, two sets of experiments were performed: the secretion of VEGF protein from HepG2 in the presence of various concentrations of IP 6 ( Figure 5B), and the secretion of VEGF from cancer cells that were pre-treated with several doses of IP 6 for 24 h, and then cultured without IP 6 for an additional 24 h ( Figure 5C ). IP 6 decreased the secreted VEGF contents in the conditioned medium after 24 h by about 50% (p = 0.012) ( Figure 5B) in a concentration-dependent manner. This inhibitory effect on VEGF expression was more dramatic in HepG2 cells pre-treated with IP 6 . These cells continued to grow in serum-free media without IP 6 . After 24 h, 1.0 mM IP 6 induced a 79% reduction in VEGF secretion (p = 0.02), while 86% reduction was observed with 2.0 mM IP 6 (p = 0.015) ( Figure 5C ).
DISCUSSION
Angiogenesis plays a central role in a variety of physiologic and pathologic conditions, such as cancer, vascular, rheumatoid and other disease. Because the presence of an adequate blood supply is required for the growth and metastasis of malignant tumors, the inhibition of tumor-induced angiogenesis represents a promising target for anti-neoplastic therapy; thus, angiogenesis-suppressing agents may provide a new modality of anti-tumor treatment (35) . These novel agents can treat not only cancer, but any other disease involving hyper-angiogenesis. Although a number of pharmacological inhibitors are under investigation, the possible toxicities and a need for chronic dosing dictate a search for novel agents with low toxicity that are effective and safe for long-term use. Recently it was observed that a series of substances proposed as possible cancer preventive agents show anti-angiogenic properties; therefore, a novel concept "angioprevention" was proposed (58) .
IP 6 , a natural carbohydrate that is abundant in the diet, possesses significant cancer preventive and therapeutic activity (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . Along with inhibition of cell proliferation, IP 6 enhances differentiation of malignant cells to a more mature cells, often resulting in reversion to normal phenotype (1, (10) (11) (12) 25, 26) . In this study, we investigated the anti-angiogenic potential of IP 6 , which may critically contribute to its cancer preventive and therapeutic efficacy. We show that IP 6 can target both endothelial and cancer cells. Our data demonstrate that IP 6 inhibited the growth and induced differentiation of vascular endothelial cells, and inhibited the secretion of the angiogenic factor VEGF by malignant epithelial cells.
IP 6 inhibited FGF-stimulated angiogenesis in vivo, which indicates that IP 6 may suppress abnormal angiogenesis. In vitro inhibition of endothelial cell growth by IP 6 additionally implies that IP 6 inhibits excessive angiogenesis via this route as well, since proliferation of endothelial cells is vital for capillary sprouting. Furthermore, IP 6 inhibited and prevented vascular network formation of HUVECs on Matrigel beds in vitro. It is important to note that the inhibitory effect of IP 6 on tube formation was observed whether the treatment was initiated simultaneous with seeding cells on the Matrigel or after the tubes had formed. The ability of IP 6 to disrupt the integrity of pre-formed tubes indicates that IP 6 may not only prevent, but also regress new blood vessels. Capillary formation is a complex process requiring cell-matrix interactions, inter-cellular communications, as well as cell motility; therefore, the reduced network formation may indicate inhibition of attachment, migration, and invasion of endothelial cells. Work is in progress to elucidate the effect of IP 6 on these processes. Furthermore, the results of the in vivo Matrigel angiogenesis assay, showing significantly smaller plugs, containing markedly less vascular cell infiltration, suggest that the inhibition of endothelial cell proliferation may be central to suppression of angiogenesis and tumor growth by IP 6 . Although no toxicity or distinct morphology associated with apoptotic endothelial cells could be detected, we are not excluding the possibility that at higher doses IP 6 might induce apoptosis (59) of endothelial cells, as well.
In addition to these inhibitory effects on the responses of endothelial cells, and in vivo and in vitro angiogenesis, IP 6 exerted inhibitory action on the secretion of angiogenic cytokines. Angiogenesis can be inhibited, and consequently tumor growth may be reduced, by blocking the induction of VEGF or fibroblast growth factor (FGF) (34) . VEGF induces angiogenesis in both pathologic and physiologic situation; it has a narrow specificity, and acts with specific mitogenic and chemotactic effects on vascular endothelial cells, thereby promoting their proliferation and permeability.
Here we have investigated the effects of IP 6 on secretion of VEGF from HepG2 cells, human liver cancer cells, and found that IP 6 reduces the expression of VEGF mRNA and protein. Very recently, Singh et al. (58) also reported the inhibition of VEGF by IP 6 in a prostate tumor model. FGF is another factor implicated in tumor growth and angiogenesis. Morrison et al. (61) investigated the effect of IP 6 on FGF and found that IP 6 was a potent antagonist of FGF cellular binding and activity. They attributed this activity to the chair conformation of IP 6 , which mimics that of the pyranose ring structure of heparin. Interestingly, VEGF is also a heparin-binding angiogenic factor.
We have previously shown that IP 6 was effective in the treatment of liver cancer in vitro and in vivo in nude mice (26, 27) . A dose-dependent growth inhibition of HepG2 cells was induced by IP 6 in vitro (26) , and a reduction of transplanted hepatoma tumor growth in mice given intra-tumoral injections of IP 6 (27) . In a model of human rhabdomyosarcoma, IP 6 -treated nude mice produced 25-to 49-fold smaller tumors when compared to controls (25) . Therefore, it is possible that IP 6 , by depriving tumor endothelium of VEGF and FGF, may disrupt the formation of new vessels by inhibiting the secretion of angiogenic factors leading to tumor growth inhibition. Higher levels of basal VEGF mRNA have been detected in hepatocellular carcinoma than in normal tissues, including the major VEGF isoforms 121 and 165 (62) . Three mRNA VEGF isoforms were expressed in HepG2 cells. Increased expression of VEGF and VEGF 121, 165, and 189 mRNA isoforms is associated with tumor progression in hepatocellular carcinoma (62) and the formation of liver metastases with poor prognosis (62, 63) . It is important to note that IP 6 dramatically down-regulated the expression of all three VEGF mRNA isoforms. These data further raise questions about the possible effects of IP 6 on VEGF steadystate levels and under experimental conditions associated with over-expression of VEGF, such as hypoxia. Hypoxia can be detected in the central regions of tumors, and is an important stimulus for new vessel formation. It is also critically involved in the process of metastasis. Hypoxia up-regulates VEGF expression partly through increasing mRNA transcription; within tumors, VEGF mRNA co-localizes to hypoxic regions (57) . The VEGF gene and several other genes regulated by hypoxia are under the control of the hypoxia-inducible factor (HIF)-1, a transcription factor (64) . Therefore, it will be important to investigate the effect of IP 6 on HIF-1 expression and function in hypoxia.
Several molecular mechanisms can be suggested for the observed anti-angiogenic effect of IP 6 and its inhibition of VEGF expression. IP 6 may down-regulate VEGF acting directly, or indirectly by inhibiting the expression of factors up-stream of VEGF. Various signal transduction pathways have been implicated in angiogenesis, and in the regulation of angiogenic factor expression. Phosphatidylinositol 3'-kinase (PI3K)/Akt is a common signaling pathway for oncogenes and tumor suppressor genes and is involved in VEGF and HIF-1 regulation (64) . Activation of Erk1 and Erk2 has also been shown to be important mediator for up-regulation of VEGF (65, 66) . Although both pathways have been shown to be inhibited by IP 6 (59, (67) (68) (69) , further study is required to define more precisely the mechanism of anti-angiogenic action of IP 6 related to these pathways. The potential of IP 6 to inhibit PI3K may be related to its structure, because IP 6 is similar to D-3-deoxy-3-fluoro-PtdIns, a PI3K inhibitor (67) . However, IP 6 is also known to be a strong metal ion chelator (1) (2) (3) (4) (5) , and may inhibit metalloproteinases, which is necessary for capillary sprouting (70). Furthermore, since some receptor kinases depend on divalent cations for their activity, IP 6 could inhibit the activity of these kinases by chelating the divalent cations, affecting both Erks and PI3K/Akt pathways. Higher levels of basal mRNA and protein of both VEGF and insulin-like growth factor-II (IGF-II), another angiogenic factor, can be detected in hepatocellular carcinoma relative to normal tissue (62) . Kar et al. (71) demonstrated an interaction between IP 6 and IGF-II receptor binding sites in rat brain. It has been reported that the combination of hypoxia and IGF-II induces VEGF mRNA (72), and that IGF-II can up-regulate HIF-1 protein; therefore it is possible that IP 6 interfering with IGF-II may further contribute to the observed down-regulation of VEGF.
Cancer therapy that combines distinct inhibitors of angiogenesis is a novel, effective strategy for the experimental treatment of cancer. To develop more successful anti-angiogenic therapy, combined treatment, directed to different cellular compartments may be important. It is hoped that the combination of these angiogenesis inhibitors with cytotoxic and differentiating chemotherapeutic agents will significantly improve survival and quality of life for not just cancer patients, but also of others affected by enhanced angiogenesis.
In conclusion, this study shows that IP 6 has inhibitory action on several angiogenic responses, including growth and differentiation of endothelial cells, as well as inhibitory effects on the secretion of VEGF, a key angiogenic cytokine. This anti-angiogenic activity, combined with the previously known potential of IP 6 as a strong anti-proliferative and differentiation-inducing agent, provides evidence that IP 6 is useful for prevention and therapy of cancers and other conditions of excessive angiogenesis in humans, and merits further investigation. Matrigel mixed with 200 ng/mL bFGF without (A) and with 2 mM IP 6 in RPMI (B) was injected s.c. into C57BL/6J mice. Arrows indicate the area of cellular infiltration and functional neovessel formation within Matrigel in cross-section after 7 days. This area is wider with new vessels filled with red blood cells in plugs of Matrigel in combination with bFGF (positive control) (A). However, IP 6 in the presence of bFGF almost completely prevented the vessel induction, indicating that IP 6 potently suppressed the bFGF-stimulated angiogenesis in mice (B) (M = Matrigel plug). As a result of IP 6 -suppressed cellular infiltration and functional neovessel formation within the Matrigel plugs, the relative cellular density of plugs was significantly smaller, with a 75% reduction in the IP 6 -treated group compared to control (p < 0.001) (C). Each data point represents the vascular density from up to five different slides and five regions per slide (n = 10-15; p < 0.001 for bFGF+IP 6 relative to bFGF). Figure 5 . IP 6 inhibits VEGF expression and secretion. HepG2 cells were treated with 0, 0.5, 1 and 2 mM IP 6 for 8 h, and VEGF mRNA levels were assessed by RT-PCR; a dose-response down-regulation of VEGF was observed. Total RNA was analyzed for VEGF and GAPDH mRNA. The VEGF primers identified three isoforms of VEGF mRNA transcripts, and all three isoforms were markedly down-regulated by IP 6 relative to GAPDH (p < 0.001). Note that smaller amount of mRNA from control cells than those from experimental cells were used for RT-PCR because of too high density for VEGF (A). Representative time course of IP 6 effects on VEGF protein secretion by HepG2 cells in serum-free media (B). Confluent cells in T25 flasks were treated with increasing concentrations of IP 6 . At designated time points, 1 ml aliquots were taken for VEGF protein determination by ELISA. IP 6 significantly decreased secreted VEGF after 24 h (p = 0.012) (B). HepG2 cells pretreated with 2 mM IP 6 for 24 h exhibited a 86% reduction in VEGF secretion after 48 h (p = 0.015) (C). 
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